We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTransense Regulatory News (TRT)

Share Price Information for Transense (TRT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 95.00
Bid: 93.00
Ask: 97.00
Change: 0.00 (0.00%)
Spread: 4.00 (4.301%)
Open: 95.00
High: 95.00
Low: 95.00
Prev. Close: 95.00
TRT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Share Repurchase Programme

22 Feb 2022 07:01

RNS Number : 3474C
Transense Technologies PLC
22 February 2022
 

 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation 596/2014/EU (which is part of UK law by virtue of the European Union (Withdrawal) Act 2018)

 

 

Transense Technologies plc

("Transense" or "the Company")

 

Share Repurchase Programme

 

Transense Technologies plc (AIM: TRT), the developer of specialist sensor systems, is pleased to announce that it will commence a programme to conduct market purchases of ordinary shares of 10 pence each in the Company ("Ordinary Shares") up to a maximum aggregate purchase price of £300,000 (the "Programme").

 

The Company has entered into an arrangement with Shard Capital Stockbrokers ("Shard") in relation to the Programme where Shard will make the trading decisions concerning the timing of the market purchases of Ordinary Shares independently of and uninfluenced by the Company, with such trading decisions being in accordance with the terms of the Programme. Purchases may continue during any periods during the term of the Programme when the Company itself would be prohibited from dealing by the UK version of the Market Abuse Regulation 596/2014/EU (which is part of UK law by virtue of the European Union (Withdrawal) Act 2018) ("UK MAR"). The Company reserves the right to terminate the programme if at any time it deems this to be appropriate and would make an announcement in advance of so doing.

 

The Company confirms that it currently has no unpublished inside information.

 

The Programme will commence today, 22 February 2022, and will continue until 31 October 2022 unless terminated earlier.

 

The Programme will be conducted by the Company in accordance with and under the terms of the general authority granted by the Company's shareholders at the Company's Annual General Meeting on 23 November 2021 to purchase up to 1,643,774 Ordinary Shares. This authority will expire at the earlier of the end of the next Annual General Meeting of the Company or 23 February 2024.

 

Any market purchases will be conducted in compliance with the following restrictions regarding price conditions:  

· the minimum price (exclusive of any expenses) at which any Ordinary Share may be purchased shall be its nominal value of 10 pence

· the maximum price (exclusive of any expenses) at which any Ordinary Share may be purchased shall be the higher of: (i) an amount equal to 5 per cent, above the average of the middle market quotations of an Ordinary Share as derived from the London Stock Exchange Daily Official List for the five business days immediately preceding the date of such purchase, and (ii) the higher of the price of the last independent trade and the highest current independent bid on the trading venue where the purchase is carried out.

 

Due to the limited liquidity in the Ordinary Shares, any market purchase of Ordinary Shares pursuant to the Programme on any trading day could represent a significant proportion of the daily trading volume in the Ordinary Shares on AIM and could exceed 25 per cent. of the average daily trading volume. This means that the Company will not benefit from the exemption contained in Article 5(1) of UK MAR.

 

The objective of the Programme is to offset the dilutive impact of share awards to directors and employees.

 

Ordinary Shares acquired as a result of the Programme will be held by the Company in treasury and in accordance with the Companies Act 2006, will not have any voting rights. It is anticipated that any Ordinary Shares held in treasury but surplus to unexercised option requirements from time to time will be cancelled.

For further information please visit www.transense.com or contact:

Transense Technologies plc

Nigel Rogers (Executive Chairman)

Melvyn Segal (CFO)

Via Walbrook PR

Allenby Capital (Nominated Adviser and Broker)

Jeremy Porter / George Payne (Corporate Finance)

Tony Quirke (Sales and Corporate Broking)

Tel: +44 (0)20 3328 5656

Walbrook PR

Tom Cooper/Nick Rome/Nicholas Johnson

Tel: +44 (0)20 7933 8780

Transense@walbrookpr.com

 

 

Notes to Editors:

 

Transense develops and supplies wireless sensor technology and systems. The Company has three business areas:

· SAW, patent protected Surface Acoustic Wave sensor technology that provides real time measurement of torque, temperature, pressure and strain, that is used to improve efficiency, performance and safety of propulsion systems and machinery;

· Translogik, smart, connected commercial vehicle tyre inspection equipment, used by vehicle fleets to more easily gather and maintain accurate tyre safety and condition data; and

· iTrack, a tyre pressure monitoring system for off-highway machinery, licensed exclusively to Bridgestone Corporation, the world's largest tyre producer, under a ten-year deal.

Target market sectors include automotive, aerospace and industrial machinery. The Group's strategy is to leverage excellence in innovation, know-how in wireless sensor technologies and form industry partnerships in these global growth sectors to maximise shareholder value through sustained revenue growth from all three principal technologies - SAW, iTrack and Translogik.

Transense is headquartered in Oxfordshire, UK, and was admitted to trading on AIM, a market operated by the London Stock Exchange (AIM: TRT), in 1999.

For further information please contact transense@walbrookpr.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSKFLFLLLLEBBK
Date   Source Headline
17th Apr 20246:00 pmRNSTransaction in Own Shares & TVR
15th Apr 20242:51 pmRNSTransaction in Own Shares & TVR
28th Mar 20245:00 pmRNSTotal Voting Rights
25th Mar 20243:35 pmRNSTransaction in Own Shares & TVR
20th Mar 20249:10 amRNSRyan Maughan appointed as Managing Director
29th Feb 20245:00 pmRNSTotal Voting Rights
21st Feb 20242:40 pmRNSHolding(s) in Company
19th Feb 20247:00 amRNSInterim Results & Investor Presentation
15th Feb 20247:00 amRNSHolding(s) in Company
2nd Feb 20245:41 pmRNSTransaction in Own Shares & TVR
31st Jan 20245:00 pmRNSTotal Voting Rights
12th Jan 20247:00 amRNSDirector/PDMR Shareholding
11th Jan 20249:52 amRNSTransaction in Own Shares & TVR
8th Jan 20247:00 amRNSTranslogik Update – Appointment of Sales Director
1st Dec 20237:00 amRNSGrant of share options to Director and employee
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 202311:11 amRNSDirector/PDMR Shareholding
29th Nov 20233:01 pmRNSDirector/PDMR Shareholding
29th Nov 202310:45 amRNSResult of AGM
29th Nov 20237:00 amRNSAGM Statement & Trading Update
24th Nov 20231:11 pmRNSHolding(s) in Company
9th Nov 202312:12 pmRNSDirector/PDMR Shareholding
6th Nov 20234:48 pmRNSTransaction in Own Shares & TVR
25th Oct 202310:00 amRNSPosting of Annual Report & Notice of AGM
16th Oct 20233:23 pmRNSHolding(s) in Company
3rd Oct 20236:00 pmRNSHolding(s) in Company
28th Sep 20235:22 pmRNSHolding(s) in Company
27th Sep 20233:18 pmRNSHolding(s) in Company
26th Sep 20233:37 pmRNSDirector/PDMR Shareholding
25th Sep 202311:00 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSFinal Results & Investor Presentation
22nd Sep 20239:25 amRNSHolding(s) in Company
31st Aug 20235:00 pmRNSTotal Voting Rights
29th Aug 20238:30 amRNSTransaction in Own Shares & TVR
23rd Aug 20237:00 amRNSNotice of Results & Investor Presentation
16th Aug 202310:03 amRNSHolding(s) in Company
11th Jul 20237:00 amRNSYear End Trading Update
30th Jun 20235:00 pmRNSTotal Voting Rights
22nd Jun 20234:24 pmRNSTransaction in own shares & TVR
19th Jun 20234:29 pmRNSHolding(s) in Company
16th Jun 20235:57 pmRNSTransaction in own shares & TVR
5th Jun 20237:00 amRNSSAW: Extension of scope of licence agreement
2nd Jun 20232:36 pmRNSTransaction in own shares & TVR
31st May 20235:00 pmRNSTotal Voting Rights
3rd May 20237:00 amRNSNew Automotive eDrive Business Contract
2nd May 202312:48 pmRNSAppointment of Non-Executive Director
2nd May 202310:23 amRNSTransaction in own shares & TVR
31st Mar 20235:00 pmRNSTotal Voting Rights
27th Mar 20237:00 amRNSGrant of share options to Director and employees
20th Mar 20238:49 amRNSTransaction in Own Shares & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.